NasdaqGS:BIIBBiotechs
Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention
Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma.
The deal consolidates global rights to felzartamab, an antibody in Phase 3 trials for multiple immune mediated diseases.
Biogen will lead development and commercialization of felzartamab in Greater China, a key market for conditions such as IgAN and PMN.
For investors tracking Biogen, this move adds a late stage immunology asset to a pipeline already focused on serious...